Noxopharm Limited (ASX:NOX)
Australia · Delayed Price · Currency is AUD 0.0650
-0.0020 (-2.99%)
Sep 18, 2026, 1:54 PM AEST
Noxopharm Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Other Revenue | 1.43 | 2.82 | 2.4 | 6.01 | 5.43 |
| 1.43 | 2.82 | 2.4 | 6.01 | 5.43 | |
Revenue Growth | -49.40% | 17.52% | -60.06% | 10.71% | -3.20% |
Cost of Revenue | 1.94 | 4.27 | 2.94 | 10.65 | 7.78 |
Gross Profit | -0.52 | -1.45 | -0.53 | -4.64 | -2.35 |
Selling, General & Admin | 2.9 | 3.94 | 4.07 | 5.85 | 7.17 |
Operating Expenses | 2.92 | 3.94 | 4.07 | 6.01 | 7.43 |
Operating Income | -3.44 | -5.39 | -4.6 | -10.64 | -9.78 |
Interest Expense | -1.14 | -0.5 | -0.03 | -0.04 | -0.08 |
Interest & Investment Income | 0.02 | 0.01 | 0.01 | 0.08 | 0.05 |
Other Non Operating Income (Expenses) | -0.33 | 0.53 | - | - | - |
EBT Excluding Unusual Items | -4.89 | -5.35 | -4.63 | -10.6 | -9.81 |
Gain (Loss) on Sale of Investments | - | 0.47 | 1.05 | -4.45 | -8.86 |
Other Unusual Items | 0.43 | - | - | - | - |
Pretax Income | -4.46 | -4.88 | -3.58 | -15.06 | -18.67 |
Earnings From Continuing Operations | -4.46 | -4.88 | -3.58 | -15.06 | -18.67 |
Net Income | -4.46 | -4.88 | -3.58 | -15.06 | -18.67 |
Net Income to Common | -4.46 | -4.88 | -3.58 | -15.06 | -18.67 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 297 | 292 | 292 | 292 | 291 |
Shares Outstanding (Diluted) | 297 | 292 | 292 | 292 | 291 |
Shares Change | 1.65% | - | - | 0.35% | 10.37% |
EPS (Basic) | -0.01 | -0.02 | -0.01 | -0.05 | -0.06 |
EPS (Diluted) | -0.01 | -0.02 | -0.01 | -0.05 | -0.06 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -2.71 | -5.82 | -0.68 | -10.95 | -13.73 |
Free Cash Flow Per Share | -0.01 | -0.02 | -0.00 | -0.04 | -0.05 |
Gross Margin | -36.13% | -51.25% | -22.28% | -77.14% | -43.27% |
Operating Margin | -240.86% | -190.96% | -191.71% | -177.12% | -180.14% |
Profit Margin | -312.17% | -173.15% | -149.07% | -250.52% | -343.86% |
Free Cash Flow Margin | -190.06% | -206.48% | -28.51% | -182.13% | -252.98% |
EBITDA | -3.44 | -5.38 | -4.6 | -10.49 | -9.52 |
EBITDA Margin | -240.74% | -190.89% | -191.64% | -174.55% | -175.32% |
D&A For EBITDA | 0 | 0 | 0 | 0.15 | 0.26 |
EBIT | -3.44 | -5.39 | -4.6 | -10.64 | -9.78 |
EBIT Margin | -240.86% | -190.96% | -191.71% | -177.12% | -180.14% |